Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS 1.34% 316.17 Delayed Quote.-15.95%
SANOFI 0.69% 65.87 Real-time Quote.-8.95%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
04/23REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
04/12REGENERON PHARMACEUTICALS : EMA to Review Cemiplimab as a Potential Treatment fo..
AQ
04/12FINDINGS ON PSORIASIS REPORTED BY IN : A Systematic Review)
AQ
04/11DIABETIC RETINOPATHY DRUG MARKET PRO : Global Diabetic Retinopathy Drug Market B..
AQ
04/09REGENERON PHARMACEUTICALS : to Report First Quarter 2018 Financial and Operating..
PR
04/06SANOFI : - EMA to review cemiplimab as a potential treatment for advanced cutane..
AQ
04/05SANOFI : - EMA to review Dupixent as potential treatment for inadequately contro..
AQ
04/04REGENERON PHARMACEUTICALS : EMA to Review DUPIXENT (dupilumab) as Potential Trea..
AQ
03/29REGENERON PHARMACEUTICALS : and Alnylam Pharmaceuticals Announce Collaboration t..
AQ
03/29REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Demonstrates Positive T..
AQ
More news
News from SeekingAlpha
04/23Unity Biotechnology Finalizes $85 Million IPO Terms 
04/23OAKMARK EQUITY AND INCOME FUND : Q1 2018 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
Financials ($)
Sales 2018 6 386 M
EBIT 2018 2 470 M
Net income 2018 1 709 M
Finance 2018 3 115 M
Yield 2018 -
P/E ratio 2018 21,47
P/E ratio 2019 18,34
EV / Sales 2018 4,84x
EV / Sales 2019 4,09x
Capitalization 34 033 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 418 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-15.95%34 033
GILEAD SCIENCES3.31%96 498
VERTEX PHARMACEUTICALS5.89%40 290
GENMAB20.17%12 599
BEIGENE LTD (ADR)73.75%9 087
BLUEBIRD BIO INC-8.48%8 410